Minireviews
Copyright ©The Author(s) 2024.
World J Gastrointest Oncol. Mar 15, 2024; 16(3): 643-652
Published online Mar 15, 2024. doi: 10.4251/wjgo.v16.i3.643
Table 1 Studies of immunoscore role in patients receiving adjuvant chemotherapy
Ref.
CRC stage
ACT
IS predictive role (DFS)
Church et al[27]IIImFOLFOX, 3 vs 6 months3-yr DFS: 3 months IS high/IS low HR = 1.80 (95%CI: 1.25-2.60); 6 months IS high/IS low HR = 2.00 (95%CI: 1.38-2.92)
Pagès et al[28]IIImFOLFOX, 3 vs 6 monthsDFS: IS Int + high: HR = 0.53; 95%CI: 0.37-0.75; P = 0.0004; IS low: HR = 0.84, P = 0.269
Mlecnik et al[29]II, III5-FUIS 2-3 III stage: HR = 2.69 (1.02-7.11) P = 0.038; IS 2-3 II: HR = 1.47 (0.35-6.18) P: Non-significant; IS4/IS0-1: No effect of ACT was detected
Pagès et al[30]IIImFOLFOX, 3 vs 6 months3-yr DFS: T1-3, N1, IS high 91.4% vs 80.9%, P = 0.01; T1-3, N1, IS low 77.5% vs 74.5%, P = 0.56; T4/N2 IS high 72.0% vs 56.0%, P = 0.006; T4/N2 IS low 58.2% vs 52.6%, P = 0.2
Table 2 Studies of immunoscore in different tumor types
Ref.
Tumor
Number of patients, n
Test
Result
Ghiringhelli et al[69], 2023NSCLC133IS-ICCorrelation IS and PFS (HR = 0.39, 95%CI: 0.26-0.59, P < 0.0001), OS (HR = 0.42, 95%CI: 0.27-0.65, P < 0.0001). 36-month PFS IS-high 34%, IS-low 0%
Antoniotti et al[65], 2022CRC216IS-ICIS-high + ICI - OS HR = 0.39, 95%CI: 0.18-0.84, P < 0.001
Bifulco et al[70], 2014Melanoma190IS-ICCorrelation CD8+, PD-L1- and OS P = 0.04